Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results for OREX
5.30
-0.08 (-1.49%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.23 - 5.49
52 week 4.59 - 7.84
Open 5.35
Vol / Avg. 0.00/2.49M
Mkt cap 591.16M
P/E     -
Div/yield     -
EPS -0.81
Shares 111.54M
Beta 2.51
Inst. own 90%
Jun 27, 2014
Orexigen Therapeutics, Inc. Annual Shareholder Meeting - 1:00PM EDT - Add to calendar
Jun 23, 2014
Orexigen Therapeutics, Inc. Annual Shareholder Meeting (Estimated) Add to calendar
May 5, 2014
Q1 2014 Orexigen Therapeutics, Inc. Earnings Release (Estimated) Add to calendar
Mar 12, 2014
Q4 2013 Orexigen Therapeutics, Inc. Earnings Conference Call - Webcast
Mar 12, 2014
Q4 2013 Orexigen Therapeutics, Inc. Earnings Release
Mar 5, 2014
Orexigen Therapeutics, Inc. at Cowen Health Care Conference - Webcast
Feb 13, 2014
Orexigen Therapeutics, Inc. at Leerink Swann Global Healthcare Conference - Webcast
Feb 11, 2014
Orexigen Therapeutics, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -2507.00% -2265.78%
Operating margin -2445.27% -2251.98%
EBITD margin - -2249.24%
Return on average assets -64.83% -48.65%
Return on average equity -244.14% -132.40%
Employees 50 -
CDP Score - -

Address

Suite 200, 3344 N. Torrey Pines Court
LA JOLLA, CA 92037
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Joseph P. Hagan Acting Chief Financial Officer, Treasurer, Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Heather D. Turner Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Preston Klassen M.D. Head of Global Contrave Program, Senior Vice President - Product Development
Age: 44
Bio & Compensation  - Reuters
Mark D. Booth Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 48
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 72
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 49
Bio & Compensation  - Reuters